Skip to main content
Article thumbnail
Location of Repository

A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor

By Sophie Chabot, Nabila Jabrane-Ferrat, Karine Bigot, Julie Tabiasco, Alexandra Provost, Muriel Golzio, Muhammad Zaeem Noman, Jérôme Giustiniani, Elisabeth Bellard, Stéphanie Brayer, Maryse Aguerre-Girr, Fabienne Meggetto, Sylvie Giuriato, François Malecaze, Stéphane Galiacy, Jean-Philippe Jaïs, Olivier Chose, Jean Kadouche, Salem Chouaib, Justin Teissié, Marc Abitbol, Armand Bensussan and Philippe Le Bouteiller


A monoclonal anti-CD160 antibody inhibits the growth of new vessels in pathological ocular and tumor neoangiogenesis but not in healthy tissues

Topics: Article
Publisher: The Rockefeller University Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2006). Corneal avascularity is due to soluble VEGF
  2. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes.
  3. the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther.
  4. (2004). Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset.
  5. (2008). Modes of resistance to anti-angiogenic therapy.
  6. (2009). receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.
  7. (2005). Angiogenesis in life, disease
  8. (2009). Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.